NCT06003088View on ClinicalTrials.gov

Relative Bioavailability and Pharmacodynamics of HSK7653 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

August 12, 2022

Study Completion Date

September 9, 2022

Conditions
Healthy
Interventions
DRUG

HSK7653(5mg)

Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.

DRUG

HSK7653(25mg)

Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.

Trial Locations (1)

Unknown

The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY